Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Oct 29

PMID 33113890

Citations 14

Authors

Ayesha Atiq

Ishwar Parhar

Affiliations

Soon will be listed here.

Abstract

Clinically, gliomas are classified into four grades, with grade IV glioblastoma multiforme being the most malignant and deadly, which accounts for 50% of all gliomas. Characteristically, glioblastoma involves the aggressive proliferation of cells and invasion of normal brain tissue, outcomes as poor patient prognosis. With the current standard therapy of glioblastoma; surgical resection and radiotherapy followed by adjuvant chemotherapy with temozolomide, it remains fatal, because of the development of drug resistance, tumor recurrence, and metastasis. Therefore, the need for the effective therapeutic option for glioblastoma remains elusive. Previous studies have demonstrated the chemopreventive role of naturally occurring pharmacological agents through preventing or reversing the initiation phase of carcinogenesis or arresting the cancer progression phase. In this review, we discuss the role of natural phytochemicals in the amelioration of glioblastoma, with the aim to improve therapeutic outcomes, and minimize the adverse side effects to improve patient's prognosis and enhancing their quality of life.

Citing Articles

A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules.

Afshari A, Sanati M, Aminyavari S, Keshavarzi Z, Ahmadi S, Oroojalian F Inflammopharmacology. 2025; .

PMID: 39955698 DOI: 10.1007/s10787-025-01666-5.

Harnessing Arsenic Derivatives and Natural Agents for Enhanced Glioblastoma Therapy.

Yuan B, Kikuchi H Cells. 2025; 13(24.

PMID: 39768226 PMC: 11674460. DOI: 10.3390/cells13242138.

Advances in nano-delivery of phytochemicals for glioblastoma treatment.

Ambele M, Maebele L, Mulaudzi T, Kungoane T, Damane B Discov Nano. 2024; 19(1):216.

PMID: 39718730 PMC: 11668727. DOI: 10.1186/s11671-024-04172-9.

Novel Natural Inhibitors for Glioblastoma by Targeting Epidermal Growth Factor Receptor and Phosphoinositide 3-kinase.

Ullah A, Ullah S, Waqas M, Khan M, Ur Rehman N, Khalid A Curr Med Chem. 2024; 31(40):6596-6613.

PMID: 38616761 DOI: 10.2174/0109298673293279240404080046.

Molecular dynamics exploration of Lupenone: therapeutic implications for glioblastoma multiforme and alzheimer's amyloid beta pathogenesis.

Almohaimeed H, Almars A, Al Abdulmonem W, Alghsham R, Aljohani A, Alharbi Y Metab Brain Dis. 2023; 39(1):77-88.

PMID: 38129732 DOI: 10.1007/s11011-023-01319-y.

References

Singh-Gupta V, Joiner M, Runyan L, Yunker C, Sarkar F, Miller S . Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer. J Thorac Oncol. 2011; 6(4):688-98. DOI: 10.1097/JTO.0b013e31821034ae. View

Pardridge W . Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2004; 3(2):90-105, 51. DOI: 10.1124/mi.3.2.90. View

Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V . Mechanisms of immunomodulation in human glioblastoma. Immunotherapy. 2011; 3(4 Suppl):42-4. DOI: 10.2217/imt.11.39. View

Wu C, Lin G, Lin Z, Zhang J, Liu S, Zhou C . Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma. World J Surg Oncol. 2015; 13:97. PMC: 4358863. DOI: 10.1186/s12957-015-0496-7. View

Wang S, Zhang J, Chen M, Wang Y . Delivering flavonoids into solid tumors using nanotechnologies. Expert Opin Drug Deliv. 2013; 10(10):1411-28. DOI: 10.1517/17425247.2013.807795. View

Liao C, Lai I, Kuo H, Chuang S, Lee H, Whang-Peng J . Epigenetic Modification and Differentiation Induction of Malignant Glioma Cells by Oligo-Fucoidan. Mar Drugs. 2019; 17(9). PMC: 6780514. DOI: 10.3390/md17090525. View

Mao H, LeBrun D, Yang J, Zhu V, Li M . Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012; 30(1):48-56. PMC: 3799884. DOI: 10.3109/07357907.2011.630050. View

Palmerston Mendes L, Gaeti M, de Avila P, de Sousa Vieira M, Dos Santos Rodrigues B, Marcelino R . Multicompartimental nanoparticles for co-encapsulation and multimodal drug delivery to tumor cells and neovasculature. Pharm Res. 2013; 31(5):1106-19. DOI: 10.1007/s11095-013-1234-x. View

Vega-Stromberg T . Chemotherapy-induced secondary malignancies. J Infus Nurs. 2003; 26(6):353-61. DOI: 10.1097/00129804-200311000-00004. View

10.

Schmidt F, Knobbe C, Frank B, Wolburg H, Weller M . The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol Rep. 2008; 19(4):1061-6. View

11.

Mansour A, Daba A, Baddour N, El-Saadani M, Aleem E . Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen. J Cancer Res Clin Oncol. 2012; 138(9):1579-96. DOI: 10.1007/s00432-012-1224-0. View

12.

Huang W, Lin J, Hsieh J, Chou S, Lai C, Yun E . Nanoparticle Targeting CD44-Positive Cancer Cells for Site-Specific Drug Delivery in Prostate Cancer Therapy. ACS Appl Mater Interfaces. 2016; 8(45):30722-30734. DOI: 10.1021/acsami.6b10029. View

13.

Hoffman R, Burns 3rd W, Paper D . Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydrate l-carrageenan. Cancer Chemother Pharmacol. 1995; 36(4):325-34. DOI: 10.1007/BF00689050. View

14.

Vengoji R, Macha M, Batra S, Shonka N . Natural products: a hope for glioblastoma patients. Oncotarget. 2018; 9(31):22194-22219. PMC: 5955138. DOI: 10.18632/oncotarget.25175. View

15.

Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

16.

Michaud-Levesque J, Bousquet-Gagnon N, Beliveau R . Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res. 2012; 318(8):925-35. DOI: 10.1016/j.yexcr.2012.02.017. View

17.

Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z . Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016; 35:23. PMC: 4736617. DOI: 10.1186/s13046-016-0303-5. View

18.

Paw I, Carpenter R, Watabe K, Debinski W, Lo H . Mechanisms regulating glioma invasion. Cancer Lett. 2015; 362(1):1-7. PMC: 4435977. DOI: 10.1016/j.canlet.2015.03.015. View

19.

Lv Y, Song Q, Shao Q, Gao W, Mao H, Lou H . Comparison of the effects of marchantin C and fucoidan on sFlt-1 and angiogenesis in glioma microenvironment. J Pharm Pharmacol. 2012; 64(4):604-9. DOI: 10.1111/j.2042-7158.2011.01430.x. View

20.

Naz S, Imran M, Rauf A, Orhan I, Shariati M, Iahtisham-Ul-Haq . Chrysin: Pharmacological and therapeutic properties. Life Sci. 2019; 235:116797. DOI: 10.1016/j.lfs.2019.116797. View